Gloriane Schnabolk1,2, Mee Keong Beon2, Stephen Tomlinson1,3, Bärbel Rohrer1,2,4. 1. 1 Division of Research, Ralph H. Johnson VA Medical Center , Charleston, South Carolina. 2. 2 Department of Opthalmology, Medical University of South Carolina , Charleston, South Carolina. 3. 3 Department of Microbiology and Immunology, Medical University of South Carolina , Charleston, South Carolina. 4. 4 Department of Neurosciences Division of Research, Medical University of South Carolina , Charleston, South Carolina.
Abstract
PURPOSE: The membrane attack complex (MAC) in choriocapillaris (CC) and retinal pigment epithelium (RPE) increase with age and disease (age-related macular degeneration). MAC assembly can be inhibited by CD59, a membrane-bound regulator. Here we further investigated the role of CD59 in murine choroidal neovascularization (CNV), a model involving both CC and RPE, and tested whether CR2-CD59, a soluble targeted form of CD59, provides protection. METHODS: Laser-induced CNV was generated in wild type and CD59a-deficient mice (CD59-/-). CNV size was measured by optical coherence tomography, and CR2-CD59 was injected intraperitoneally. Endogenous CD59 localization and MAC deposition were identified by immunohistochemistry and quantified by confocal microscopy. Cell-type-specific responses to MAC were examined in retinal pigment epithelial cells (ARPE-19) and microvascular endothelial cells (HMEC-1). RESULTS: CD59 levels were severely reduced and protein was mislocalized in the RPE surrounding the lesion. CNV lesion size and subretinal fluid accumulation were exacerbated in CD59-/- when compared with those in WT mice, and an increase in MAC deposition was noted. In contrast, CR2-CD59 significantly reduced both structural features of CNV severity. In vitro, MAC inhibition in ARPE-19 cells prevented barrier function loss and accelerated wound healing and cell adhesion, whereas in HMEC-1 cells, CR2-CD59 decelerated wound healing and cell adhesion. CONCLUSION: These data further support the importance of CD59 in controlling ocular injury responses and indicate that pharmacological inhibition of the MAC with CR2-CD59 may be a viable therapeutic approach for reducing complement-mediated ocular pathology.
PURPOSE: The membrane attack complex (MAC) in choriocapillaris (CC) and retinal pigment epithelium (RPE) increase with age and disease (age-related macular degeneration). MAC assembly can be inhibited by CD59, a membrane-bound regulator. Here we further investigated the role of CD59 in murine choroidal neovascularization (CNV), a model involving both CC and RPE, and tested whether CR2-CD59, a soluble targeted form of CD59, provides protection. METHODS: Laser-induced CNV was generated in wild type and CD59a-deficient mice (CD59-/-). CNV size was measured by optical coherence tomography, and CR2-CD59 was injected intraperitoneally. Endogenous CD59 localization and MAC deposition were identified by immunohistochemistry and quantified by confocal microscopy. Cell-type-specific responses to MAC were examined in retinal pigment epithelial cells (ARPE-19) and microvascular endothelial cells (HMEC-1). RESULTS:CD59 levels were severely reduced and protein was mislocalized in the RPE surrounding the lesion. CNV lesion size and subretinal fluid accumulation were exacerbated in CD59-/- when compared with those in WT mice, and an increase in MAC deposition was noted. In contrast, CR2-CD59 significantly reduced both structural features of CNV severity. In vitro, MAC inhibition in ARPE-19 cells prevented barrier function loss and accelerated wound healing and cell adhesion, whereas in HMEC-1 cells, CR2-CD59 decelerated wound healing and cell adhesion. CONCLUSION: These data further support the importance of CD59 in controlling ocular injury responses and indicate that pharmacological inhibition of the MAC with CR2-CD59 may be a viable therapeutic approach for reducing complement-mediated ocular pathology.
Authors: Bärbel Rohrer; Qin Long; Beth Coughlin; Brandon Renner; Yuxiang Huang; Kannan Kunchithapautham; Viviana P Ferreira; Michael K Pangburn; Gary S Gilkeson; Joshua M Thurman; Stephen Tomlinson; V Michael Holers Journal: Adv Exp Med Biol Date: 2010 Impact factor: 2.622
Authors: Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Andrea Giani; Aristomenis Thanos; Mi In Roh; Edward Connolly; George Trichonas; Ivana Kim; Evangelos Gragoudas; Demetrios Vavvas; Joan W Miller Journal: Invest Ophthalmol Vis Sci Date: 2011-06-01 Impact factor: 4.799
Authors: Nalini S Bora; Sankaranarayanan Kaliappan; Purushottam Jha; Qin Xu; Baalasubramanian Sivasankar; Claire L Harris; B Paul Morgan; Puran S Bora Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: M Elvington; P Blichmann; F Qiao; M Scheiber; C Wadsworth; I Luzinov; J Lucero; A Vertegel; S Tomlinson Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330
Authors: Benjamin J Kim; Dimitrios C Mastellos; Yafeng Li; Joshua L Dunaief; John D Lambris Journal: Prog Retin Eye Res Date: 2020-12-13 Impact factor: 19.704